OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials
Yao Neng Teo, Adriel Z. H. Ting, Yao Hao Teo, et al.
American Journal of Cardiovascular Drugs (2022) Vol. 22, Iss. 3, pp. 299-323
Closed Access | Times Cited: 23
Yao Neng Teo, Adriel Z. H. Ting, Yao Hao Teo, et al.
American Journal of Cardiovascular Drugs (2022) Vol. 22, Iss. 3, pp. 299-323
Closed Access | Times Cited: 23
Showing 23 citing articles:
SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients
Pasquale Mone, Fahimeh Varzideh, Stanislovas S. Jankauskas, et al.
Hypertension (2022) Vol. 79, Iss. 8, pp. 1633-1643
Open Access | Times Cited: 135
Pasquale Mone, Fahimeh Varzideh, Stanislovas S. Jankauskas, et al.
Hypertension (2022) Vol. 79, Iss. 8, pp. 1633-1643
Open Access | Times Cited: 135
Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart
Gaetano Santulli, Fahimeh Varzideh, Imma Forzano, et al.
Hypertension (2023) Vol. 80, Iss. 9, pp. 1800-1809
Open Access | Times Cited: 39
Gaetano Santulli, Fahimeh Varzideh, Imma Forzano, et al.
Hypertension (2023) Vol. 80, Iss. 9, pp. 1800-1809
Open Access | Times Cited: 39
SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations
Pietro Maffei, Silvia Bettini, Luca Busetto, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 3579-3598
Open Access | Times Cited: 19
Pietro Maffei, Silvia Bettini, Luca Busetto, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 3579-3598
Open Access | Times Cited: 19
Efficacy and safety of once daily oral administration of sodium‐glucose cotransporter‐2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats
Stijn Niessen, H.S. Kooistra, Yaiza Forcada, et al.
Journal of Veterinary Internal Medicine (2024) Vol. 38, Iss. 4, pp. 2099-2119
Open Access | Times Cited: 6
Stijn Niessen, H.S. Kooistra, Yaiza Forcada, et al.
Journal of Veterinary Internal Medicine (2024) Vol. 38, Iss. 4, pp. 2099-2119
Open Access | Times Cited: 6
Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes
Francesco Piccirillo, Marina Lanciotti, Annunziata Nusca, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2103-2103
Open Access
Francesco Piccirillo, Marina Lanciotti, Annunziata Nusca, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2103-2103
Open Access
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
Imma Forzano, Scott Wilson, Angela Lombardi, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 9, pp. 839-847
Closed Access | Times Cited: 10
Imma Forzano, Scott Wilson, Angela Lombardi, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 9, pp. 839-847
Closed Access | Times Cited: 10
To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases
Wen-Ling Lee, Peng‐Hui Wang, Szu‐Ting Yang, et al.
Journal of the Chinese Medical Association (2022)
Open Access | Times Cited: 14
Wen-Ling Lee, Peng‐Hui Wang, Szu‐Ting Yang, et al.
Journal of the Chinese Medical Association (2022)
Open Access | Times Cited: 14
Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis
Jiyifan Li, Chenyang Zhu, Jingru Liang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Jiyifan Li, Chenyang Zhu, Jingru Liang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
Peng Zhong, Jingjing Zhang, Yanzhao Wei, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e22423-e22423
Open Access | Times Cited: 6
Peng Zhong, Jingjing Zhang, Yanzhao Wei, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e22423-e22423
Open Access | Times Cited: 6
The impact of sodium–glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials
Yao Hao Teo, Alys Z. Q. Chia, Yao Neng Teo, et al.
Journal of Hypertension (2022) Vol. 40, Iss. 12, pp. 2353-2372
Closed Access | Times Cited: 10
Yao Hao Teo, Alys Z. Q. Chia, Yao Neng Teo, et al.
Journal of Hypertension (2022) Vol. 40, Iss. 12, pp. 2353-2372
Closed Access | Times Cited: 10
Sotagliflozin Promotes Anti-oxidant Properties in the Kidneys of Type 1 Diabetic Akimba Mice
Lakshini Y. Herat, Jennifer R. Matthews, Ana Sarvi Darimi, et al.
(2024)
Open Access | Times Cited: 1
Lakshini Y. Herat, Jennifer R. Matthews, Ana Sarvi Darimi, et al.
(2024)
Open Access | Times Cited: 1
Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects
Mohammad Belal Omari, Shafiqullah Naseri, Abdul Jalil Hassan
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 1131-1141
Open Access | Times Cited: 1
Mohammad Belal Omari, Shafiqullah Naseri, Abdul Jalil Hassan
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 1131-1141
Open Access | Times Cited: 1
Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?
Theocharis Koufakis, Michael Doumas, Pantelis Zebekakis, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1497-1502
Closed Access | Times Cited: 6
Theocharis Koufakis, Michael Doumas, Pantelis Zebekakis, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1497-1502
Closed Access | Times Cited: 6
Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus
Hsiao‐Huai Kuo, Yau‐Huei Lai, Po‐Lin Lin, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Hsiao‐Huai Kuo, Yau‐Huei Lai, Po‐Lin Lin, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 2
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: A Review
Rachel Porth, Karina Oelerich, Mala S. Sivanandy
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1056-1056
Open Access
Rachel Porth, Karina Oelerich, Mala S. Sivanandy
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1056-1056
Open Access
Pharmacological Mechanisms of Periplocae Cortex Against Congestive Heart Failure Based on Network Pharmacology and Experimental Evaluation
Xiaojing Zhang, Zhi‐Jie Liu, Baojian Guo, et al.
Natural Product Communications (2024) Vol. 19, Iss. 3
Open Access
Xiaojing Zhang, Zhi‐Jie Liu, Baojian Guo, et al.
Natural Product Communications (2024) Vol. 19, Iss. 3
Open Access
Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion
Hiromi Sato, Akimichi Ishikawa, Hideki Yoshioka, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Hiromi Sato, Akimichi Ishikawa, Hideki Yoshioka, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
PET Imaging of Sodium-Glucose Cotransporters (SGLTs): Unveiling Metabolic Dynamics in Diabetes and Oncology
Konrad Klimek, Xinyu Chen, Takanori Sasaki, et al.
Molecular Metabolism (2024) Vol. 90, pp. 102055-102055
Open Access
Konrad Klimek, Xinyu Chen, Takanori Sasaki, et al.
Molecular Metabolism (2024) Vol. 90, pp. 102055-102055
Open Access
Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials’ meta-analysis studies
Pouria Khashayar, Farid Farahani Rad, Ozra Tabatabaei‐Malazy, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access
Pouria Khashayar, Farid Farahani Rad, Ozra Tabatabaei‐Malazy, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access
Does evidence from RCTs suggest: SGLT2 inhibitors could not reduce myocardial infarction and stroke?
Lixin Du, Zhigang Li, Lan Peng, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 10, pp. 1703-1704
Closed Access | Times Cited: 1
Lixin Du, Zhigang Li, Lan Peng, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 10, pp. 1703-1704
Closed Access | Times Cited: 1
Dual Blockade of the Renin-Angiotensin System in Glomerular Diseases
Antonietta Gigante, Rosario Cianci
Current Vascular Pharmacology (2023) Vol. 21, Iss. 2, pp. 75-77
Closed Access
Antonietta Gigante, Rosario Cianci
Current Vascular Pharmacology (2023) Vol. 21, Iss. 2, pp. 75-77
Closed Access
Different safety profiles for SGLT-2 vs SGLT-1/2 inhibitors for T2DM
Reactions Weekly (2022) Vol. 1900, Iss. 1, pp. 7-7
Closed Access
Reactions Weekly (2022) Vol. 1900, Iss. 1, pp. 7-7
Closed Access
